News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Apr 18, 2018
London, UK, Carlsbad, CA, April 19, 2018 – GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary canna
Apr 12, 2018
- Long-Term Safety and Efficacy Data in Patients with Lennox-Gastaut Syndrome and Dravet Syndrome to be Presented -
Mar 15, 2018
London, UK, Carlsbad, CA, March 13, 2018 – GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary canna
Mar 05, 2018
London, UK, Carlsbad, CA, 5 March, 2018: GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Ju
Feb 27, 2018
London, UK, Carlsbad, CA, February 27, 2018 – GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary ca
Feb 21, 2018
-Study did not meet its primary endpoint- -Company remains committed to continued development of GWP42006 for autism spectrum disorders and will continue to explore the product’s potential within the field of epilepsy -
Feb 06, 2018
London, UK, Carlsbad, CA, 6 Feb., 2018: GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Jus
Feb 05, 2018
- Epidiolex® (cannabidiol) NDA and MAA applications accepted for review – - NDA PDUFA goal date scheduled for June 27, 2018 -
Feb 05, 2018
– MAA seeking regulatory approval of Epidiolex for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome –
Jan 29, 2018
London, UK, 29 January 2018: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 February, 2018 it

Pages